US Patent 9260501 Peptide extended insulins
Patent 9260501 was granted and assigned to Novo Nordisk on February, 2016 by the United States Patent and Trademark Office.
All edits
Edits on 14 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 4 Dec, 2023
Golden AI
Edits made to:
Article (+104 characters)
Article
Patent abstract
Insulins to which there is connected an amino acid oligomer have satisfactory properties.
Edits on 29 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Jan Markussen0
Thomas Børglum Kjeldsen0
Thomas Høeg-Jensen0
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09260501 Peptide extended insulins US Patent 9260501 Peptide extended insulins
Infobox
Patent Number
09260501
Patent Number
9260501
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 5 Jan, 2022
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 09260501 Peptide extended insulins
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
09260501
Date of patent
February 16, 2016
Patent application number
12312132
Date Filed
October 29, 2007
Patent primary examiner
Find more entities like US Patent 9260501 Peptide extended insulins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
